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Abstract: Vascular aging is characterized by increase in arterial sti↵ness and remodeling of the arterial
wall with a loss of elastic properties. Silicon is an essential trace element highly present in arteries. It is
involved in the constitution and stabilizationof elastinfibers. Thenutritional supply andbioavailability
of silicon are often inadequate. Spirulina (Sp), micro algae have recognized nutritional properties
and are able to incorporate minerals in a bioavailable form. We evaluated the e↵ects of nutritional
supplementation with silicon-enriched spirulina (SpSi) on arterial system structure and function in
hypertension. Experiments were performed on hypertensive (SHR) and normotensive Wistar-Kyoto
(WKY) rats supplemented with SpSi or Sp over a period of three months. Arterial pressure, vascular
function and morphometric parameters of thoracic aorta were analyzed. SpSi supplementation
lowered arterial pressure in SHR and minimized morphometric alterations induced by hypertension.
Aortic wall thickness and elastic fibers fragmentation were partially reversed. Collagen and elastin
levels were increased in associationwith extracellularmatrix degradation decrease. Vascular reactivity
was improved with better contractile and vasorelaxant responses to various agonists. No changes
were observed in SHR supplemented with Sp. The beneficial e↵ects of SpSi supplementation
evidenced here, may be attributable to Si enrichment and o↵er interesting opportunities to prevent
cardiovascular risks.
Keywords: spirulina; silicon; hypertension; arterial structure; vascular function
1. Introduction
Silicon (Si), a major trace element and essential nutrient for humans, is beneficial in bone formation
and connective tissue health especially vascular tissue [1,2]. Aorta, tendons, skin, and bones are rich in
Si with aortic tissue containing four to five times more Si than liver, heart, and muscle tissues in rats [3].
Si content significantly declines with age in aorta and connective tissues in several animal species [4]
and humans [5,6], especially women [7]. This reported decrease with age and disease progression
could be related to a potential deficiency in intake. Silicon was established as an essential nutrient
since the 1970’s, and compelling evidence continues to accumulate indicating that silicon contributes
to health [8]. Data from human and animal studies demonstrate that dietary silicon increases bone
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mineralization and collagen synthesis, improves structural integrity of connective tissue and reduces
the risk of atherosclerosis [9–12]. Food is the major source of silicon for humans with higher intakes
obtained from plant-based foods rather than animal products [13]. However, due to changes in dietary
practices, silicon intake in humans has decreased [14]. Supplementation with bioavailable forms
of Si has proven therapeutic potential in the prevention of degenerative processes, especially bone
demineralization and atherosclerosis [15]. Moreover, besides intake level, the bioavailability of Si is of
paramount importance and not always established. Si exists in mineral and soluble forms. The mineral
form (SiO2) is insoluble and poorly available. The water soluble form which is absorbed by humans is
the orthosilicic acid (Si(OH)4). It is obtained from fluids (water, beer) or by hydrolysis of silicon from
solid foods in the gastrointestinal tract. Food is the major source of available Si and much of the silicon
consumed is poorly soluble with limited nutritional impact. Thus, the development of new functional
nutrients to improve nutritional status and mitigate nutritional deficiencies is of interest.
New types of food supplements based on organic biomass such as yeast, lactobacilli, or spirulina,
have been developed and could serve as rich sources of bioavailable trace elements [16]. Among them,
Spirulina (Sp) is emerging as a potential resource of functional food. Sp is a species of filamentous
cyanobacteria that has long been consumed as a food supplement. The genius, Spirulina platensis,
is primarily used due to its high protein and vitamin contents [17]. Apart from its nutritional and health
properties, Sp possesses the ability to incorporate and accumulate trace elements in a soluble form that
is bioavailable in mammals. This has been previously shown for selenium, iron and manganese [16].
Incorporating the soluble form of Si into spirulina is a way to obtain a bioavailable food supplement
providing the beneficial e↵ects of silicon and the antioxidant and anti-inflammatory properties of
Sp [18]. The beneficial e↵ects of silicon enriched-spirulina (SpSi) were previously demonstrated on
disorders and dysfunctions induced by a high-fat diet in the Syrian hamster model [19]. The positive
e↵ects on vascular function were especially attributed to Si enrichment. It is well established that
obesity is associated with functional and structural changes in the vascular wall [20]. Such structural
changes occur during hypertension, resulting in increased arterial sti↵ness and decreased vascular
compliance. The reduction of elastic properties is associated with the remodeling and rearrangement of
structural main components of the vascular wall and extracellular matrix [21]. The most predominant
mechanisms thought to underlie these changes are an increase in collagen deposition and a breakdown
of elastin [22].
Considering the biological role of Si, we evaluated the e↵ects of SpSi nutritional supplementation
on cardiovascular system alterations induced by hypertension in the spontaneously hypertensive rat
(SHR).
2. Materials and Methods
2.1. Spirulina and Tablet Supplements
Spirulina platensis (Sp) and silicon-enriched Spirulina platensis (SpSi) were produced by
PhycoBiotech (Montpellier, France). The complete production process of SpSi is protected by a
patent filed by Phyco-Biotech. Sp were grown in raceway ponds in Zarouk’s medium at 22  C and pH
10.5 and in the presence of 1 g/L sodium metasilicate (Na2SiO3) for Si-enrichment as described [19].
The biomass recovered by filtration was then washed, cut, quickly dried at 42  C in a vented dryer,
finely grinded and used as a powder. As indicated by the manufacturer, the final Si contents were 2%
for Sp-Si and less than 0.023% (Si detection limit) for Sp and orthosilic acid Si(OH)4 is the predominant
form present in spirulina.
Spirulina powders (Sp and SpSi) were used to prepare the dietary supplements as previously
described [23]. Compact dough made by mixing Sp or SpSi powders with standard rat chow (Safe Diet
A03, France) and water, was spread and cut into 3 mm diameter discs. The tablets obtained after drying
at 40  C for 24 hours had a constant weight of 30 ± 2 mg. Their Sp or SpSi content was determined
relatively to the Si daily need estimated around 40 mg for humans (70 kg) with a correspondence to
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15 mg Sp and 0.3 mg Si (2%) for a 500 g rat. Tablets composition was adapted to the body weight of the
rat throughout the experiment (400–500 g). Control tablets were prepared exclusively with standard
rat chow (0.2% Si).
2.2. Animals and Experimental Design
Experiments were performed on 12 weeks old male normotensive Wistar-Kyoto (n = 15) and
hypertensive SHR (n = 45) rats housed under conditions of controlled temperature (22–24  C), humidity
(45%–50%) and light cycle (12 light hours/12 dark hours) with standard food and tap water ad libitum.
Hypertensive animals were randomly separated in three groups of 15 individuals supplemented for
12 weeks with either control (SHR) or Sp (SHR-Sp) or SpSi (SHR-SpSi) tablets. Normotensive animals
were supplemented with control tablets (WKY). Tablets were administered daily by gavage with
small forceps. Body weight was monitored weekly. All experimental procedures were conducted in
accordance with the European Union Laboratory Animal Care Rules (2010/63/EU Directive) and were
approved by the local ethical committee of Montpellier (APAFIS#3922-2016020317052023).
2.3. Arterial Pressure
At the end of the protocol, animals were anesthetized by intraperitoneal injection of pentobarbital
(Invasive blood pressure was measured via cannulation of the right carotid artery using a pressure
transducer connected to a monitor (AD Instruments, Paris, France). Diastolic and systolic arterial
pressures were recorded.
2.4. Sampling and Plasma Assay
Animals were sacrificed by exsanguination through the pressure catheter. The thoracic aorta
was removed immersed in PSS bu↵er and cleaned of fat and connective tissue. Aortic tissue was
then cut into 2–3 mm width rings used either directly for vascular reactivity experiments, fixed in
4% PFA for histological analysis or frozen in liquid nitrogen then sored at  80  C for further RNA
extraction. Blood samples were centrifuged for 20 minutes at 4000 g at 4  C and plasma were frozen for
further determination of IL-6 and IL-1b with Elisa kit according to manufacturer instructions (Thermo
Scientific, Saint Herblain, France).
2.5. Echocardiography
High resolution echocardiography (VisualSonics/Fujifilm, Canada with a MS250D ultrasound
probe 20 MHz) was performed under anesthesia by 2% isofluorane inhalation at 37  C, and under
ECG and respiratory rate monitoring, as previously described [24]. Left ventricular (LV) parasternal
long axis 2D views in B-mode and M-Mode were performed at the level of papillary muscle to assess
LV wall thicknesses and internal diameters allowing the calculation of the ejection fraction (EF) and
LV wall thickness. EF was calculated using Teichholz formula [100 ⇥ (LVIDd3   LVIDs3)/LVIDd3].
The LV mass (corrected) was calculated as LV Mass = 1053 ⇥ [(LVIDd+LVPWd+IVSd)3   LVIDd3].
O✏ine image analyses were performed using dedicated VisualSonics VevoLab 3.1.0 software.
2.6. Histological Staining and Morphometric Analysis
Thoracic aortic segments of 3 mm length were taken 0.5 cm downstream of the aortic cross,
fixed in 4% PFA embedded in para n, and cut into 5 µm serial cross-sections with a microtome.
Adjacent sections were stained with Verhoe↵’s solution, the first step in Van Gieson staining which
highlights elastic laminae, or picrosirius red dye (PSR) to examine collagen. Stains were also used for
morphometric measurements within the media layer. Optical bright field images were acquired with a
slide scanner (Nanozoomer, Hamamatsu) and were digitally analyzed with simple image software
(ImageJ, NIH USA) for morphometric analysis and elastin fibers level quantification. Internal and
external perimeters of the tunica intima-media weremeasured using ImageJ to further calculate internal
Nutrients 2019, 11, 2574 4 of 14
and external diameters andmedia thickness. Elastin content was determinedwithin each ring after fiber
identification by direct pixel quantification using the software. Data are presented as relative density
expressed as percentage of the total media section area. Elastin fiber fragmentation was performed
with a custom routine running with ImageJ software based on the plugin AnalyseSkeleton [25]. Elastin
fibers were detected and fiber fragments were counted and normalized to the analyzed surface area in
each preparation.
The PSR-stained sectionswere imaged under polarized light at⇥ 20magnification, and birefringent
collagen fibers were quantitated (in yellow/red collagen I and in green collagen III). Total collagen
contents were determined by direct pixel quantification with ImageJ in a sample field (four fields per
section) and normalized with the total media area within the field.
2.7. Quantitative PCR
Aortic tissue was homogenized in TRI Reagent (Sigma Aldrich, Saint-Quentin Fallavier, France).
RNA was isolated after extraction with chloroform, precipitation with isopropanol and washes with
ethanol. RNA was then reverse transcribed with the Verso cDNA Synthesis Kit (Thermo Fisher
Scientific, Illkirch, France). Quantitative PCR of cDNA was performed in triplicate with a SYBR
Green based assay (Roche Diagnostics, Mannheim, Germany). The following primers were used:
collagen1, (F) 50-AACCTGGATGCCATCAAGG-30 and (R) 50- AACTGGAATCCATCGGTCAT-30;
elastin, (F) 50-GCAGCCTGGCGTCTTG-30 and (R) 50-GGATAATAGACTCCACCGGGA-30; MMP-9,
(F) 50- CTGCAGTGCCCTTGAACTAA-30 and (R) 50- TATCCGGCAAACTAGCTCCT-30. The expression
was normalized to endogenous RPLPO (Ribosomal Large Protein) expression (ThermoFischer Scientific,
Illkirch, France). The data are reported as relative quantification using the ddCt method. Primer
sequences are available as Supporting Information.
2.8. Vascular Reactivity
Experiments were performed on freshly isolated rat aortas and as previously described [19].
Arterial segments were mounted between two stainless steel hooks placed in a conventional vertical
organ bath chamber filled with 5 mL of PSS, maintained at 37  C and continuously bubbled with
O2. Changes in isometric tension were measured using an IT1-25 force transducer and an IOX
computerized system (EMKA Technologies, Paris, France). Each arterial segment was subjected to
a 60-min equilibration period at a basal resting tension of 2 g. Arterial contractility was evaluated
with phenylephrine (PE, 10 6 M). The functionality of the endothelium was assessed by the ability of
acetylcholine (Ach, 10 6 M) to induce relaxation in PE-contracted rings. After washout and a 20–30 min
period of stabilization, the contractile and vasorelaxant abilities of the aorta were respectively evaluated
with cumulative increases in the concentration of the depolarizing agent KCl (1 to 80 mM) and PE
(10 9 to 10 5 M) before and after preincubation with N(!)-nitro-L-arginine methyl ester (L-NAME,
10 5 M) or the muscarinic agonists Ach (10 8 to 10 5 M) and the NO donor sodium nitroprusside (SNP,
10 9 to 10 6 M). Aortic rings were previously contracted with a submaximal dose of PE (10 6 M) prior
to Ach and SNP. The rate of relaxation was expressed as the percentage of the PE-induced contraction.
2.9. Statistical Analysis
Four groups were analyzed: normotensive rats supplemented with a control tablet (WKY),
hypertensive rats supplemented with a control tablet (SHR), hypertensive rats supplemented with
spirulina (SHR-Sp) and hypertensive rats supplemented with silicon-enriched spirulina (SHR-SpSi),
n = 15 for all groups. Data were expressed as mean ± s.e.m and analyzed using GraphPad Prism (V6.05,
RRID:SCR_002798) with one-way ANOVA followed by Tukey’s post-hoc test to compare all groups.
Dose-response curves were fitted with nonlinear regressions and statistical di↵erences were assessed
using two-way ANOVA followed by Bonferroni’s post-hoc test to compare all groups. Statistical
analysis shown compared WKY to SHR treated or not and SHR-SpSi to other groups to evaluate the
e↵ects of SpSi. P values lower than 0.05 were considered significant.
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3. Results
3.1. E↵ect of Supplementation on Blood Pressure
Elevated systolic, diastolic and mean arterial pressures validated hypertension in SHR (Figure 1
and Table 1). Systolic and diastolic arterial pressures were 64 mmHg (64%) and 63 mmHg (75%) higher
than in WKY, respectively. Animals supplemented with SpSi had mean arterial pressures lower than
SHR but still higher than WKY (Table 1). In SHR-SpSi, systolic pressure was 32 mmHg (18%) lower
than in SHR and 28 mmHg (25%) higher than in WKY. For diastolic pressure, values were 35 mmHg
(24%) lower and 27 mmHg (24%) higher than in SHR andWKY, respectively. No di↵erence was noticed
on arterial pressure in the SHR-Sp group vs. SHR. Thus, no e↵ect of Sp supplementation was observed.
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Figure 1. E↵ect of supplementation on arterial pressure. Blood systolic (a) and diastolic (b) arterial
pressures were measured for all animals in each group (n = 15). Values are in mmHg and data are
presented as scatter plots with mean ± s.e.m. **** p < 0.0001, *** p < 0.001, ** p < 0.01 vs. WKY;
§§§§ p < 0.0001, §§§ p < 0.001 vs. SHR-SpSi.
Table 1. E↵ect of supplementation on body weight, arterial pressure and cardiac morphological and
functional parameters.
WKY SHR SHR-Sp SHR-SpSi
Body weight (g) 473.8 ± 6.8 441.1 ± 6.2 **, § 464.6 ± 5.8 475.1 ± 10.3
Body weight gain (g) 137.2 ± 4.6 104.6 ± 6.2 * 121.3 ± 8.4 113.2 ± 5.6
Mean arterial pressure (mmHg) 95.2 ± 2.5 157.1 ± 3.2 ****, §§§§ 160.2 ±6.6 ****, §§§§ 123.2 ±5.5 ***
Cardiac Frequency (bpm) 348 ± 7 329 ± 7 347 ± 5 339 ± 7
Ejection Fraction (%) 68.8 ± 2.2 60.3 ± 1.6 ** 60.8 ± 1.2 ** 62.1 ±1.5 *
Left ventricular mass (mg) 851 ± 45 1010 ± 43 * 1041 ± 39 972 ± 43
Post wall thickness, diastole ( m) 1.65 ± 0.06 2.03 ± 0.07 *** 2.19 ± 0.04 *** 2.02 ± 0.06 ***
Post wall thickness, systole (mm) 2.84 ± 0.11 3.17 ± 0.12 3.17 ± 0.07 3.13 ± 0.08
Data are mean ± s.e.m (n = 15). **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05 vs. WKY; §§§§ p < 0.0001, § p < 0.05
vs. SHR-SpSi.
3.2. Morphometric and Ultrastructural Analysis of the Vascular Wa l
We evaluated morphol gy of the art ri l wall and extracellula matrix structure and composition
by histol gical staining of aortic secti ns. Elastin staining showed that aortic wall ultrast u ture is
modified in SHR. We observed increased elastin fiber fragm ntation and linea izatio (F gure 2a).
These al erations, still present in SHR-Sp, were normalized in SHR-SpSi. Elastin fragmentation rat o
was higher in SHR and SHR-Sp (1.265 ± 0.065 and 1.384 ± 0.098 respectively) than in WKY and
SHR-SpSi (0.902 ± 0.062 and 0.853 ± 0.088 respectively) with no di↵erence observed between these
two groups (p = 0.978), showing e ciency of SpSi up lementation. Moreover, in SHR-SpSi like in
WKY, elas in fibers presented multiple refolding and wave shapes that were not observed in SHR
and SHR-Sp.
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Figure 2. E↵ect of supplementation on morphology and ultrastructure of aorta. Images show
representative histological staining of aortic samples. Bright field images illustrate (a) aorta stained
with Verhoe↵’s solution and evidencing elastin fibers structure and media thickness (scale bar 300 µm);
(b) aorta stained with picrosirius red and showing internal and external diameters (scale bar 500 µm);
(c) Picrosirius red stained sections illuminated under polarized light to visualize type I collagen in
yellow/red and type III collagen in green (scale bar 100 µm). (d) Graph showing media thickness
in all groups; data are presented as box and whiskers with median and SD. Bar graphs (e) and (f)
summarize, respectively, elastin and collagen density quantified from 3 to 5 sections per aorta and
expressed as relative ratio normalized to media layer surface. Data are presented as mean ± s.e.m
(n = 15 in each group). **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05 vs. WKY; §§§ p < 0.001,
§§ p < 0.01, § p < 0.05 vs. SHR-SpSi.
Furthermore, morphometric measurements revealed important changes in the vessel wall of
SHR. Media thickness and internal lumen diameter were increased respectively by 25% and 16%
when compared to WKY (Figure 2a–d). Inter al lumen dia eter, measured from 1512 ± 17 µm in
WKY to 1758 ± 21 µm (p < 0.0001) in SHR. With Sp supplementation no changes wer observed
for both thickness (Figure 2d) and internal diame er (1719 ± 22 µm, p = 0.635) vs. SHR. However,
media thickening and ao tic wall hypertrophy were both reduced in the SHR group supplemented
with SpSi when compared to SHR. Thickeni g was d cre ed by 70% and diameter enlarged by 55%
(1622 ± 11 µm, p < 0.0001). Though, wh n compare to WKY, those parameters were not complet ly
normalized. Internal diameter remain d large in SHR-SpSi group (p = 0.0033), yet media hypertrophy
was reversed as no di↵erence was obs rved with WKY for thickness (p = 0.386).
3.3. Analysis of Extracellular Matrix Components
Si is said to be associated with the elastin and collagen components of the aortic wall matrix. As
we observed ultrastructural changes in elastic fibers, we determined elastin and collagen density ratios
in our histological stained sections and quantified their mRNA tissue levels. Both elastin and collagen
density were decreased in SHR vs. WKY (Figure 2e,f). This was associated with a decrease in mRNA
level for elastin (Figure 3a), while no change was found for collagen mRNA level (Figure 3b). SpSi
supplementation in SHR corrected elastin and collagen density with ratios that were higher than in
SHR (Figure 2e,f). No di↵erence was observed when compared to WKY. For elastin, this was associated
to a change in mRNA elastin level which was intermediate between WKY and SHR (Figure 3a).
No di↵erence was noticed for collagen mRNA level. Furthermore, no e↵ect of Sp supplementation
was found in SHR on both collagen and elastin fiber density and mRNA level.
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Figure 3. E↵ect of supplementation on aortic mRNA levels of various extracellular matrix components.
The mRNA expression levels were quantified by qPCR in rat aorta for elastin (a), collagen I (b) and
MMP-9 (c). Graphs represent mean ± s.e.m of three di↵erent determinations in each animal of all
groups (n = 15). **** p < 0.0001, ** p < 0.01 vs. WKY; § p < 0.05 vs. SpSi.
Matrix metalloproteases (MMPs) participate in vascular tissue remodeling. MMPs activity
contributes to the disassembly of intercellular junctions and the degradation of extracellular matrix
components. Among them, MMP-9 may be overexpressed in SHR [26]. Thus we also quantified
MMP-9 mRNA levels in the di↵erent groups. We observed that this level was indeed higher in SHR
than in WKY (Figure 3c, p = 0.0051). SpSi supplementation reduced MMP-9 mRNA overexpression
compared to SHR without reaching significance (p = 0.6038). SpSi mRNA level was di↵erent from Sp
level (p = 0.0399) and intermediate between WKY (p = 0.0895) and SHR. No di↵erence was observed
for SHR-Sp vs. SHR.
The remodeling of extracellular matrix in SHR consisting of increased degradation and decreased
expression of elastin and collagen was partially corrected by SpSi supplementation.
3.4. Evaluation of Vascular Contractile Properties of Aorta
The contractility of aortic rings was evaluated using the depolarizing agent KCl and the
↵-adrenergic agonist PE. The contractile response to KCl was impaired in SHR when compared
to WKY (Figure 4a). Maximal contractility was decreased by 30 ± 8% in SHR, with lower Emax value
(p = 0.005) (Figure 4a inset and Table 2). In hypertensive animals, we also observed a significant
rightward shift in the dose-response curve (Figure 4a) with a diminution of EC50 value reflecting an
increased sensitivity to KCl-induced depolarization (p = 0.0055 vs. WKY, Table 2). These alterations
were attenuated by SpSi supplementation. The maximal contractile response to KCl was restored.
Emax value was higher than that of SHR (p = 0.0292) and not di↵erent from that of WKY (p = 0.8612).
KCl-sensitivity was normalized as shown by EC50 value being no di↵erent from that of WKY (p = 0.935)
but increased when compared to SHR (p = 0.0221). No di↵erence was observed for KCl response and
sensitivity between SHR-Sp and SHR with identical Emax and EC50 values (Table 2).
However, sensitivity and contractile responses to PE were not changed in SHR when compared
to WKY (Figure 4b). Emax and EC50 values were identical between these groups (Table 2).
Therefore, no di↵erence was noticed with Sp and SpSi supplementations.
N
utrients2019,11,2574
8
of14
N
utrients 2019, 11, x FO
R PEER
 R
EV
IEW
 
7 of 13 
 level (p = 0.0399) and interm
ediate betw
een W
K
Y (p = 0.0895) and SH
R. N
o difference w
as observed 
for SH
R-Sp vs. SH
R.  
The rem
odeling of extracellular m
atrix in SH
R
 consisting of increased degradation and 
decreased expression of elastin and collagen w
as partially corrected by SpSi supplem
entation. 
 
Figure 3. Effect of supplem
entation on aortic m
RN
A
 levels of various extracellular m
atrix 
com
ponents. The m
RN
A
 expression levels w
ere quantified by qPC
R in rat aorta for elastin (a), 
collagen I (b) and M
M
P-9 (c). G
raphs represent m
ean ± s.e.m
 of three different determ
inations in each 
anim
al of all groups (n = 15). **** p < 0.0001, ** p < 0.01 vs. W
K
Y; § p < 0.05 vs. SpSi. 
3.4. Evaluation of Vascular Contractile Properties of A
orta  
The contractility of aortic rings w
as evaluated using the depolarizing agent K
C
l and the α-
adrenergic agonist PE. The contractile response to K
C
l w
as im
paired in SH
R w
hen com
pared to W
K
Y 
(Figure 4a). M
axim
al contractility w
as decreased by 30 ± 8%
 in SH
R, w
ith low
er E
m
ax value (p = 0.005) 
(Figure 4A
 inset and Table 2). In hypertensive anim
als, w
e also observed a significant rightw
ard shift 
in the dose-response curve (Figure 4a) w
ith a dim
inution of EC
50 value reflecting an increased 
sensitivity to K
C
l-induced depolarization (p = 0.0055 vs. W
K
Y, Table 2). These alterations w
ere 
attenuated by SpSi supplem
entation. The m
axim
al contractile response to K
C
l w
as restored. E
m
ax 
value w
as higher than that of SH
R (p = 0.0292) and not different from
 that of W
K
Y (p = 0.8612). K
C
l-
sensitivity w
as norm
alized as show
n by EC
50 value being no different from
 that of W
K
Y (p = 0.935) 
but increased w
hen com
pared to SH
R
 (p = 0.0221). N
o difference w
as observed for K
C
l response and 
sensitivity betw
een SH
R-Sp and SH
R w
ith identical E
m
ax and EC
50 values (Table 2).  
H
ow
ever, sensitivity and contractile responses to PE w
ere not changed in SH
R w
hen com
pared 
to W
K
Y (Figure 4b). E
m
ax and EC
50 values w
ere identical betw
een these groups (Table 2). Therefore, 
no difference w
as noticed w
ith Sp and SpSi supplem
entations.  
 
Figure 4. Effect of supplem
entation on contractile response of aorta. (a) C
urves sum
m
arize 
cum
ulative dose-responses to K
C
l in aortic rings from
 W
K
Y (w
hite sym
bol), SH
R (black sym
bol), 
SH
R-Sp (grey sym
bol) and SH
R-SpSi (dotted grey sym
bol). The inset show
s the m
axim
al K
C
l-induced 
contraction expressed in gram
s. (b) Bar graph presents the m
axim
al contractions induced by PE in all 
experim
ental groups. D
ata represent m
ean ± s.e.m
 (n = 15 in each group). **** p < 0.0001, *** p < 0.001, 
** p < 0.01 vs. W
K
Y; §§§ p < 0.001, §§ p < 0.01, § p < 0.05 vs. SH
R-SpSi. 
Figure
4.E
↵ectofsupplem
entation
on
contractile
response
ofaorta.(a)C
urvessum
m
arize
cum
ulative
dose-responsesto
K
C
lin
aortic
ringsfrom
W
K
Y
(w
hite
sym
bol),
SH
R
(black
sym
bol),SH
R
-Sp
(grey
sym
bol)and
SH
R
-SpSi(dotted
grey
sym
bol).The
insetshow
s
the
m
axim
alK
C
l-induced
contraction
expressed
in
gram
s.(b)Bar
graph
presents
the
m
axim
alcontractions
induced
by
PE
in
allexperim
entalgroups.D
ata
representm
ean±
s.e.m
(n
=
15
in
each
group).****p
<
0.0001,***p
<
0.001,
**p
<
0.01
vs.W
K
Y;§§§
p
<
0.001,§§
p
<
0.01,§
p
<
0.05
vs.SH
R
-SpSi.
Table
2.M
axim
alresponses
(E
m
ax )and
sensitivity
(EC
50 )for
the
various
agonists
and
antagonists
ofthe
contractile
response
on
rataorta.
K
C
l
PE
L-N
A
M
E
/PE
A
ch
SN
P
E
m
ax
(g)
EC
50
(m
M
)
E
m
ax
(g)
EC
50
(nM
)
E
m
ax
(g)
EC
50
(nM
)
E
m
ax
(%
PE)
EC
50
(µM
)
E
10-8 (%
PE)
EC
50
(nM
)
W
H
Y
2.49±
0.14
19.9±
1.4
1.4±
0.12
605±
81
2.27±
0.11
1790±
420
93.5±
0.6
36.1±
5.7
98.6±
0.3
5.7±
0.7
SH
R
1.73±
0.19
** ,§
14.1±
0.6
** ,§
1.17±
0.1
550±
114
2.26±
0.21
1736±
677
79.5±
1.7
**** ,§§§§
10.4±
2.1
97.1±
0.9
10.8±
1.5
*** ,§
SH
R
-Sp
1.69±
0.16
** ,§
13.9±
0.9
** ,§
1.18±
0.11
566±
89
2.26±
0.21
1827±
784
81.6±
1.5
**** ,§
5.7±
2.5
97.3±
0.9
12.5±
0.3
**** ,§§§
SH
R
-SpSi
2.33±
0.11
18.4±
1.04
1.31±
0.09
532±
62
1.97±
0.13
1340±
336
88.6±
1.4
22.1±
4.5
99.3±
0.3
6.9±
0.6
D
ata
are
m
ean±
s.e.m
(n
=
15).****p
<
0.0001,***p
<
0.001,**p
<
0.01,*p
<
0.05
vs.W
K
Y;
§§§§
p
<
0.0001,
§
p
<
0.05
vs.SH
R
-SpSi.
Nutrients 2019, 11, 2574 9 of 14
To estimate basal NO release in aortic segments, dose-response curves to PE were generated in the
presence of L-NAME (Figure 5a). The di↵erence in the contractile level to PE before and after addition
of L-NAME would indicate the extent of endothelial basal NO release. In all groups, we observed that
L-NAME significantly increased the contractile response to PE (Figure 5a). No di↵erence was observed
in Emax values. However, the increase was significantly greater in SHR and SHR-Sp than in WKY and
SHR-SpSi. This is indicated by the analysis of DAUC, defined as the di↵erence in the areas under the
concentration response curves of PE in the presence and in the absence of L-NAME. Thus, DAUC was
higher in SHR and in SHR-Sp than in WKY and in SHR-SpSi (Figure 5b). No di↵erence was found
between WKY and SHR-SPSi.
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Emax and EC50 values when compared to SHR. They were decreased when compared with WKY, as 
well. Additionally, we observed that Sp supplementation did not modify the changes evidenced in 
SHR. 
Similarly, SNP induced concentration-dependent relaxation in all groups (Figure 6b). The 
sensitivity of aortic smooth muscle to the NO donor was decreased in SHR as indicated by lower EC50 
value (p = 0.0009), when Emax values were identical (Table 2). SpSi supplementation corrected SNP 
sensitivity as we observed a lower EC50 value in SHR-SpSi than in SHR (p = 0.0162) and no difference 
with WKY (p = 0.7784). With Sp supplementation SNP sensitivity was not changed when compared 
to SHR.  
Figure 5. Impact of L-NAME on PE-induced contraction. (a) Cumulative dose-response curves to
PE were performed in absence (plain lines) and in presence of 10 µM L-NAME (dotted lines). Data
are expressed as mean ± s.e.m (n = 15). **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05, PE vs.
L-NAME PE. (b) Bar graph illustrates the ability of NO to attenuate PE-induced vasoconstriction and
corresponded to DAUC. It was calculated as the di↵erence in the areas under the concentration response
curves of PE in the presence and in the absence of L-NAME and was expressed as percentage of the
corresponding AUC for PE. Data are mean ± s.e.m (n = 15). ** p < 0.01, * p < 0.05 vs. WKY; §§ p < 0.01,
§ p < 0.05 vs. SHR-SpSi.
3.5. Evaluation of Vasorelaxant Capacity of the Aorta
The vasorelaxant properties of the aortawere evaluatedwithAch and SNP (Figure 6). Ach assessed
functional integrity of the endothelium. With SNP we evaluated the sensitivity of aortic muscle to NO.
Ach in uced a dose-dependent relaxation that was impaired in SHR (Figure 6a). Both the sensitivity,
as ass ssed by EC50 valu , an Emax of Ach we decreased in SHR when compared to WKY (Table 2).
The SpSi supplementation partially restored Ach sensitivity as indicated by increased Emax and EC50
values when compared to SHR. They were decreased when compared with WKY, as w ll. Additionally,
we observed that Sp upplementation did not modify the change evidenced in SHR.
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3.6. Analysis of IL-6 and IL-1B Inflammation Markers 
A link exists between inflammation and hypertension as hypertension is considered a chronic 
inflammatory disease. Considering the anti-inflammatory properties of Sp [18], we investigated the 
effects of supplementation on some markers shown to contribute to the pathogenesis of vascular 
disease (IL-6 and IL-1β) [27]. Thus, we quantified mRNA levels in our aortic samples. We found no 
significant difference in the IL-6 and IL-1β expression levels in the aorta of SHR when compared to 
WKY (Figure 7). No significant variation of mRNA levels was noticed in any group indicating no 
effect of supplementation. 
Figure 6. E↵ect of supplementation on vasorelaxant response of aorta. Cumulative dose response
curves to Ach (a) and SNP (b) in aortic rings in WKY (white symbol), SHR (black symbol), SHR-Sp
(grey symbol) and SHR-SpSi (dotted grey symbol). Bar graphs compare maximal relaxations for each
antagonist in all groups. Data is expressed as percentage of PE-induced contraction show mean ± s.e.m
(n = 15). **** p < 0.0001, *** p < 0.001, vs. WKY; §§§§ p < 0.0001, §§§ p < 0.001, § p < 0.05 vs. SHR-SpSi.
Similarly, SNP induced concentration-dependent relaxation in all groups (Figure 6b).
The sensitivity of aortic smooth muscle to the NO donor was decreased in SHR as indicated by
lower EC50 value (p = 0.0009), when Emax values were identical (Table 2). SpSi supplementation
corrected SNP sensitivity as we observed a lower EC50 value in SHR-SpSi than in SHR (p = 0.0162) and
no di↵erence with WKY (p = 0.7784). With Sp supplementation SNP sensitivity was not changed when
compared to SHR.
3.6. Analysis of IL-6 and IL-1B Inflammation Markers
A link exists between inflammation and hypertension as hypertension is considered a chronic
inflammatory disease. Considering the anti-inflammatory properties of Sp [18], we investigated the
e↵ects of supplementation on some markers shown to contribute to the pathogenesis of vascular
disease (IL-6 and IL-1 ) [27]. Thus, we quantified mRNA levels in our aortic samples. We found no
significant di↵erence in the IL-6 and IL-1  expression levels in the aorta of SHR when compared to
WKY (Figure 7). No significant variation of mRNA levels was noticed in any group indicating no e↵ect
of supplementation.
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3.7. E↵ect of Supplementation on Cardiac Morphology and Function
Echocardiography analysis showed increased left ventricular mass and post-wall thickness in SHR
(Table 1) indicating hypertrophy of the myocardium. Cardiac function was also altered as evidenced by
a decreased ejection fraction (EF). In SHR, EF of 60.3 ± 1.6% was reduced by 13% (p = 0.0032) compared
to WKY EF of 68.8 ± 2.2%. In animals supplemented with either SpSi or Sp, no change was noticed
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in those parameters when compared to SHR. In SHR-Spsi and in SHR-Sp, cardiac hypertrophy and
dysfunction were not modified.
4. Discussion
Considering the properties and biological role of silicon, we evaluated the e↵ects of nutritional
supplementation with silicon-enriched spirulina on vascular remodeling induced by hypertension in a
SHR rat model. Our study showed highly beneficial e↵ects including attenuation of arterial pressure
and improvement of vascular reactivity. These benefits were associated with reduction in arterial
thickness and sti↵ness caused by the structural remodeling of the aortic wall in SHR. They were mainly
attributable to Si enrichment.
Beneficial and safe e↵ects of SpSi supplementation were previously reported in high fat
diet-induced models of atherosclerosis in hamsters [19] and metabolic syndrome in rats [23].
Improvement of glucose tolerance, insulin resistance, or dyslipidemia were evidenced with both
SpSi and Sp supplementation. However, only SpSi had beneficial e↵ects on arterial function [19].
No toxicity or side e↵ects of SpSi supplement were otherwise observed [28]. Increase of arterial
sti↵ness, reduction of arterial compliance, and distensibility marked by fragmentation of elastin are the
main consequences of arterial remodeling occurring in hypertension, obesity and aging [29]. Vascular
remodeling in hypertension is characterized by altered ultrastructure due to reduction in elastin and
increase in fibrous tissue [30]. Here, we assessed the e↵ect of SpSi on the ultrastructural, mechanical
and functional changes characterized in SHR thoracic aorta. These modifications consisted of (i) arterial
wall hypertrophy, (ii) fragmentation, linearization, and refolding of elastic fibers, and (iii) impaired
contractile and vasorelaxant responses. These changes typified the degenerative processes leading to
the reduction of compliance and distensibility described in hypertension [22,31,32] and associated with
aging [9,33]. Indeed, in SHR aorta, our results showed enlarged internal diameter andmedia thickening,
increased elastin fragmentation ratio, and lower elastin and collagen levels than in normotensive
animals. Consequently, contractility was impaired as evidenced by the decreased response and
sensitivities to KCl-induced depolarization and PE. The vasorelaxant responses to both Ach and SNP
were also reduced. The enhanced e↵ect of L-NAME on PE-induced contraction suggested that the
decrease in the vasodilator capacity of aorta in SHR is due to both the alteration of vascular smooth
muscle function and NO bioavailability.
After three months of supplementation, SpSi substantially corrected and even normalized most of
the defects identified in SHR aorta. First, aortic hypertrophy was reduced as shown by morphologic
analysis. Higher level of elastin fiber density and mRNA level were associated to a decrease in
MMP-9 expression, suggesting that both enhanced elastin biosynthesis and reduced extracellular
matrix contributed to media thinning. It is known that hypertensive vascular remodeling involves
reorganization and impairment of the extracellular matrix and that MMPs play an important role in this
remodeling [34]. Second, we observed an improvement of vascular function after SpSi supplementation.
Contractile and vasorelaxant responses were increased in association with an increased sensitivity to
the agonists and antagonists tested and a better NO bioavailability. Finally, we found that SHR animals
supplemented with SpSi had lower arterial pressure than control SHR. Arterial pressure, although
significantly reduced, was still higher than normal pressure which may explain the lack of benefit on
cardiac parameters in our experimental conditions (hypertension already established, 3 months of
supplementation).
Another interesting result in our study is that supplementation with Sp alone had no e↵ect in SHR
suggesting that the benefits observed with SpSi are genuine e↵ects of Si. The nutritional essentiality of
Si is undeniable [10,33]. This organic element appears as an important structural component of the
aortic wall which contributes to elastin and collagen synthesis and stability [9]. Data from animal
and human studies demonstrated that dietary Si mitigates the risk of cardiovascular diseases. Si in
drinking water has been inversely correlated with mortality rates due to coronary heart diseases in
Finland [11]. Reduced damage and thickening of elastic fibers were observed in the aortic wall after
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silicon supplementation in rabbit models of diet-induced atherosclerosis [35,36]. Moreover, our results
are in line with a previous study reporting reduction in systolic arterial pressure after supplementation
with soluble silicon in SHR [37]. In that study, arterial structure was not investigated and enhancement
of intracellular magnesium uptake was evoked as a possible mechanism. This is not inconsistent with
our findings as Si is supposed to contribute to biological function and a↵ect retention or function of
other minerals, such as aluminum or magnesium [8]. Various mechanisms are potentially involved
in the beneficial e↵ects of Si. Here, a major result in our study is that SpSi supplementation reverses
elastic fiber degradation which is likely to contribute to the overall benefit. The observed regenerative
changes of the vascular wall are in line with a Si-related beneficial e↵ect. However, quantification of Si
level in the aortic tissue is warranted to validate this hypothesis.
Increase in collagen level is also a result of SpSi supplementation. Collagen increase is often
associated with pathological remodeling of arterial structure in hypertension as well as in ageing [38],
though this change is not consistently associated with hypertension. Several reports actually show
decreases in vascular collagen with hypertension [39,40]. In our study, we found a higher aortic
collagen level in SHR-SpSi when compared to SHR but not higher than inWKY. Collagenwas not found
to be overexpressed when compared to the non-pathological condition, and this was not supposed to
be deleterious. Although, we might wonder what the e↵ects of a longer supplementation could be.
In conclusion, the reduction of arterial pressure and the structural and functional changes observed
in the aortic walls of SHR rats after SpSi supplementation demonstrated the beneficial e↵ects of this
nutritional supplement, especially Si enrichment. The altered vascular phenotype associated with
hypertension in SHR was not completely rescued but SpSi nutritional supplementation did ameliorate
some of the deleterious e↵ects. In humans, vascular disease and ageing are associated with increased
arterial pressure and structural remodeling of arteries which are seen as decline of elasticity and
distensibility, fragmentation of elastin and higher collagen-to-elastin ratio. Si supplementation is
beneficial in preventing extracellular matrix degenerative processes. Our results show clear beneficial
e↵ects of Si (enriched in spirulina) oral supplementation on those degenerative processes. Our results
open interesting perspectives for the use of SpSi supplementation in the prevention of vascular
degenerative processes and potentially ageing, as well as in di↵erent conditions of Si deficiency.
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